Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
Public ClinicalTrials.gov record NCT01877811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.
Study identification
- NCT ID
- NCT01877811
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2013
- Primary completion
- Nov 30, 2018
- Completion
- Jan 31, 2019
- Last update posted
- Apr 24, 2019
2013 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | — | — |
| University of California Irvine College of Medicine | Irvine | California | — | — |
| University of California San Diego Moores Cancer Center | San Diego | California | — | — |
| Lombardi Comprehensive Cancer Center, Georgetown | Washington D.C. | District of Columbia | — | — |
| Florida Cancer Center | Sarasota | Florida | — | — |
| University Cancer & Blood Center, LLC | Athens | Georgia | — | — |
| Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Henry Ford Health System | Detroit | Michigan | — | — |
| Karmanos Cancer Center | Detroit | Michigan | — | — |
| Washington University | St Louis | Missouri | — | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | — | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | — | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | — | — |
| University of Washington, Seattle Cancer Care Alliance | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01877811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2019 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01877811 live on ClinicalTrials.gov.